Repligen beats top-line and bottom-line estimates; updates FY26 outlook

Repligen (RGEN) reported Q3 Non-GAAP EPS of $0.53, exceeding estimates by $0.07. Revenue grew 10.9% year-over-year to $209.3M, beating expectations by $2.55M. The company raised its FY26 revenue guidance to $844-$852M, indicating growth of 14.5%-15.5%.

Original reporting
Published Oct 27, 2026, 11:08 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 11:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$RGEN
Bullish
high confidence
Mentioned
$RGEN
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$RGENBullishHigh
01

Why it matters

The earnings beat and raised FY26 outlook provide fresh data for valuation models and may trigger short-covering.

02

Market read

The new guidance could move RGEN and influence sentiment in the biotech sector.

03

What to watch

Potential dilution from future financing or execution risk on pipeline projects.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Repligen is a specialty biopharma company focused on protein purification technologies.

Company-level read

Ticker impact

$RGENBullishHigh confidence
Context

Repligen reported Q3 non‑GAAP EPS of $0.53 beating estimates and raised FY26 revenue guidance to $844‑$852M.

Expected impact

potential upside as market prices in higher revenue outlook

Evidence & confidence

Earnings beat and upward guidance are fresh, material information that can move the stock immediately.

Market effects

Biotech/biopharma sector may see modest uplift from a peer's strong guidance.

U.S. biotech investors could adjust exposure to similar small‑cap innovators.

Limited to investors tracking U.S. biotech earnings.

Counterpoint

If the guidance still falls short of analyst consensus, the stock could face disappointment.

Key entities

  • Repligen

    Biotech firm reporting Q3 results.

Related articles

$RGENMed

Stifel reiterates Buy on Repligen stock, keeps $207 target

Stifel maintained a Buy rating on Repligen (NASDAQ:RGEN) with a $207 price target, citing upside from the Biolife acquisition and strong 2027 outlook. The stock has risen 51% in six months. Repligen reported Q3 2026 earnings of $0.53 per share, beating estimates, with revenue up 11% YoY. Canaccord Genuity kept a Hold rating with a $180 target.

$RGENHighAI 8/10

RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlook

Repligen reported Q3 revenue of $209.3M, beating estimates, with adjusted EPS of $0.53 and adjusted EBITDA of $43.84M. The company raised full-year revenue guidance to $848M and adjusted EPS to $2.07. Growth was driven by proteins and chromatography segments, while filtration revenue declined. The BioLife acquisition is expected to drive future growth and margin expansion.

$RGENMed

Repligen Announces $1 Bln Convertible Notes Offering To Extend Debt Maturity

Repligen Corp. (RGEN) announced a $1 billion convertible notes offering due 2031. $541.4 million will exchange existing 2028 notes, while $458.6 million will be issued for cash. The new notes have a 20% premium conversion price. Proceeds will fund share repurchases, working capital, and potential acquisitions. The deal extends debt maturity and reduces interest expenses, benefiting EPS from 2026.